Your browser doesn't support javascript.
loading
A phase i study of DMS612, a novel bifunctional alkylating agent.
Appleman, Leonard J; Balasubramaniam, Sanjeeve; Parise, Robert A; Bryla, Christine; Redon, Christophe E; Nakamura, Asako J; Bonner, William M; Wright, John J; Piekarz, Richard; Kohler, David R; Jiang, Yixing; Belani, Chandra P; Eiseman, Julie; Chu, Edward; Beumer, Jan H; Bates, Susan E.
Afiliação
  • Appleman LJ; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Prostate Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsb
  • Balasubramaniam S; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Parise RA; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
  • Bryla C; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Redon CE; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Nakamura AJ; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Bonner WM; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Wright JJ; Investigational Drug Branch, Cancer Treatment Evaluation Program, National Cancer Institute, Bethesda, Maryland.
  • Piekarz R; Investigational Drug Branch, Cancer Treatment Evaluation Program, National Cancer Institute, Bethesda, Maryland.
  • Kohler DR; Pharmacy Department, Clinical Center, NIH, Bethesda, Maryland.
  • Jiang Y; Penn State College of Medicine, Hershey, Pennsylvania.
  • Belani CP; Penn State College of Medicine, Hershey, Pennsylvania.
  • Eiseman J; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Chu E; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Pharmacology and Chemical Biology, University of Pittsburgh
  • Beumer JH; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.
  • Bates SE; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. batess@helix.nih.gov.
Clin Cancer Res ; 21(4): 721-9, 2015 Feb 15.
Article em En | MEDLINE | ID: mdl-25467180
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzaldeídos / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzaldeídos / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article